MSK e-Tumor Board: Oligometastatic Prostate Cancer

Share
Memorial Sloan Kettering physicians present an e-tumor board, which focuses on an asymptomatic patient who has a rising prostate-specific antigen (PSA) value over an 18-month period. The team discusses clinical trial options and treatment approaches to oligometastatic prostate cancer.

The e-Tumor Boards, a video series collaboration between Medscape and Memorial Sloan Kettering Cancer Center, gives physicians an inside look into a virtual multidisciplinary tumor board case discussion.

© 2022. Medscape. Used by Permission. The content of this video is the property of Medscape. and protected by U.S. and international copyright laws. You may not copy, reproduce, distribute, transmit, modify, create derivative works, or in any other way exploit any part of this copyrighted material without the prior written permission from Medscape.